Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay Luvox Resubmission Has February Deadline; Rowasa NDA Withdrawn

Executive Summary

FDA's user fee date for action on Solvay's application for re-approval of the obsessive compulsive disorder agent Luvox (fluvoxamine) is early February

You may also be interested in...



Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma

Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma

Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out

Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel